Document is current
Any future updates will be listed below
-
Authors
Ju, Nan
Hayashi, Hiroki
Shimamura, Munehisa
Baba, Satoshi
Yoshida, Shota
Morishita, Ryuichi
Rakugi, Hiromi
Nakagami, Hironori
-
Funding
Funding for this research was provided by:
Kobayashi Foundation
Japan Agency for Medical Research and Development (A46)
- License Information
-
More Information
Article History
Received: 29 November 2021
Accepted: 18 July 2022
First Online: 21 July 2022
Competing interests
: A patent on microglial healing peptide (MHPs) for the treatment of lung fibrosis has been filed (PCT/JP2021/035368; M.S., H.N., R.M.). A patent on the MHPs as a peptide that inhibits the expression of proinflammatory cytokines has been awarded (JP6598036B2, AU2016265523A1, US10517926B2, CA2986218A1) and filed (EP3299382A1; M.S., H.N., R.M.). R.M. is a stockholder of AnGes, Funpep, and honoraria from AnGes. H.N. is a scientific advisor for Funpep. N.J., H.H., S.B., S.Y. and H.R. declare no Competing-Interest. The Department of Health Development and Medicine is an endowed department supported by AnGes, Daicel, and FunPep, and collaborates with these companies. The Department of Clinical Gene Therapy is financially supported by Novartis, AnGes, Shionogi, Boehringer, Fancl, Rohto, and FunPep.
